Rigel Pharmaceuticals (RIGL) Contract Liabilities — Quarterly & Annual

Screener

Discontinued — last reported Q3 '20

Contract Liabilities at other companies

Zevra Therapeutics, Inc.ZVRA

$0—

Mirum Pharmaceuticals, Inc.MIRM

$8.1M—

Ionis PharmaceuticalsIONS

$63.03M-49.6%

Other financials

Income statement

Revenue$58.8M+10.3%

Gross profit$54.2M+10.8%

Operating income$11.9M-7.0%

Net income$8.7M-24.4%

EPS (diluted)$0.44-30.2%

Balance sheet

Cash & equivalents$24.5M-46.6%

Total debt$68.4M+5,079%

Total equity$399.9M+2,054%

Total assets$504.6M+187%

Cash flow

Operating cash flow$2.7M+405%

CapEx$73.0K—

Free cash flow-$22.0M—

Valuation

Market cap$750.37M+25.0%

Enterprise value$794.27M+44.9%

P/E2.1×-4.1×

P/S2.5×+0.3×

Profitability

Gross margin93.4%+3.7pp

Operating margin41.6%+19.9pp

Net margin121.5%+103pp

FCF margin-61.7%—

Returns & leverage

Return on equity174.1%—

Debt / equity0.2×+0.1×

Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The source filing: Rigel Pharmaceuticals’s 10-Q, filed November 5, 2020. Open the filing →

Filed: Nov 5, 2020, 4:05 PM EST
Fiscal quarter: Q3 FY2020
Calendar quarter: Q3 2020
Accession: 0001558370-20-012838

FAQ

What does contract liabilities mean?: Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.